Toward Precision Phenotyping of Multiple Sclerosis

dc.contributor.authorPitt David
dc.contributor.authorLo Chih Hung
dc.contributor.authorGauthier Susan A.
dc.contributor.authorHickman Richard A.
dc.contributor.authorLongbrake Erin
dc.contributor.authorAiras Laura M.
dc.contributor.authorMao-Draayer Yang
dc.contributor.authorRiley Claire
dc.contributor.authorDe Jager Philip Lawrence
dc.contributor.authorWesley Sarah
dc.contributor.authorBoster Aaron
dc.contributor.authorTopalli Ilir
dc.contributor.authorBagnato Francesca
dc.contributor.authorMansoor Mohammad
dc.contributor.authorStuve Olaf
dc.contributor.authorKister Ilya
dc.contributor.authorPelletier Daniel
dc.contributor.authorStathopoulos Panos
dc.contributor.authorDutta Ranjan
dc.contributor.authorLincoln Matthew R.
dc.contributor.organizationfi=InFLAMES Lippulaiva|en=InFLAMES Flagship|
dc.contributor.organizationfi=kliiniset neurotieteet|en=Clinical Neurosciences|
dc.contributor.organization-code1.2.246.10.2458963.20.68445910604
dc.contributor.organization-code1.2.246.10.2458963.20.74845969893
dc.converis.publication-id176575066
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/176575066
dc.date.accessioned2022-10-28T13:40:14Z
dc.date.available2022-10-28T13:40:14Z
dc.description.abstract<p>The classification of multiple sclerosis (MS) has been established by Lublin in 1996 and revised in 2013. The revision includes clinically isolated syndrome, relapsing-remitting, primary progressive and secondary progressive MS, and has added activity (i.e., formation of white matter lesions or clinical relapses) as a qualifier. This allows for the distinction between active and nonactive progression, which has been shown to be of clinical importance. We propose that a logical extension of this classification is the incorporation of additional key pathological processes, such as chronic perilesional inflammation, neuroaxonal degeneration, and remyelination. This will distinguish MS phenotypes that may present as clinically identical but are driven by different combinations of pathological processes. A more precise description of MS phenotypes will improve prognostication and personalized care as well as clinical trial design. Thus, our proposal provides an expanded framework for conceptualizing MS and for guiding development of biomarkers for monitoring activity along the main pathological axes in MS.</p>
dc.identifier.eissn2332-7812
dc.identifier.jour-issn2332-7812
dc.identifier.olddbid183504
dc.identifier.oldhandle10024/166598
dc.identifier.urihttps://www.utupub.fi/handle/11111/40788
dc.identifier.urlhttps://nn.neurology.org/content/9/6/e200025
dc.identifier.urnURN:NBN:fi-fe2022102463112
dc.language.isoen
dc.okm.affiliatedauthorAiras, Laura
dc.okm.discipline3124 Neurology and psychiatryen_GB
dc.okm.discipline3124 Neurologia ja psykiatriafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherNLM (Medline)
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1212/NXI.0000000000200025
dc.relation.ispartofjournalNeurology, Neuroimmunology and Neuroinflammation
dc.relation.issue6
dc.relation.volume9
dc.source.identifierhttps://www.utupub.fi/handle/10024/166598
dc.titleToward Precision Phenotyping of Multiple Sclerosis
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
AirasEtAl2022TowardPrecisionPhenotypingOfMultipleSclerosis.pdf
Size:
439.92 KB
Format:
Adobe Portable Document Format